2024
Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV
Prunas O, Willemsen J, Warren J, Bont L, Schwartz J, Atwell J, Begier E, Dean N, Hirsch I, Karron R, Klugman K, Kramer R, Leidman E, Link-Gelles R, Nair H, Panozzo C, Pelfrene E, Simões E, Smith P, Srikantiah P, Sundaram M, Thindwa D, Vaughn D, Wilson E, Zar H, Pitzer V, Weinberger D. Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV. Vaccine X 2024, 19: 100509. DOI: 10.1016/j.jvacx.2024.100509.Peer-Reviewed Original ResearchRespiratory syncytial virusRandomized controlled trialsPreventive therapyPrevention of respiratory syncytial virusTrial designSuccess of randomized controlled trialsVaccine trial designDesign randomized controlled trialClinical trial designEstimates of vaccine efficacyPrimary endpointSyncytial virusClinical trialsVaccine efficacyControlled trialsMeta-regression modelsSelection of primary endpointsEndpointSequential trial designTherapyMultiple endpointsA low-cost culture- and DNA extraction-free method for the molecular detection of pneumococcal carriage in saliva
Peno C, Lin T, Hislop M, Yolda-Carr D, Farjado K, York A, Pitzer V, Weinberger D, Bei A, Allicock O, Wyllie A. A low-cost culture- and DNA extraction-free method for the molecular detection of pneumococcal carriage in saliva. Microbiology Spectrum 2024, 12: e00591-24. PMID: 39028185, PMCID: PMC11370248, DOI: 10.1128/spectrum.00591-24.Peer-Reviewed Original ResearchDetection of pneumococciDetection of pneumococcal carriagePneumococcal carriageCarriage surveillanceLow-resource settingsChildren attending childcare centersCarriage of pneumococciDNA extractionSaliva samplesMolecular methodsCultural enrichmentImprove surveillance effortsQPCR-based protocolPneumococcal vaccineExtraction-free methodMolecular detectionNucleic acid extractionVaccination strategiesPneumococciCulture-enrichment methodExtraction-free protocolPurified DNASalivaPaired samplesCarriagePathogen diversity and antimicrobial resistance transmission of Salmonella enterica serovars Typhi and Paratyphi A in Bangladesh, Nepal, and Malawi: a genomic epidemiological study
Dyson Z, Ashton P, Khanam F, Chirambo A, Shakya M, Meiring J, Tonks S, Karkey A, Msefula C, Clemens J, Dunstan S, Baker S, Dougan G, Pitzer V, Basnyat, Qadri F, Heyderman R, Gordon M, Pollard A, Holt K, Group S, Banda H, Biswas P, Bhuiyan A, Blohmke C, Darton T, Dolecek C, Dongol S, Mujadidi Y, Hill J, Hoang N, Jere T, Mbewe M, Msuku H, Nga T, Nkhata R, Rahman S, Rahman N, Saad N, Tan T, Thindwa D, Voysey M, Wachepa R. Pathogen diversity and antimicrobial resistance transmission of Salmonella enterica serovars Typhi and Paratyphi A in Bangladesh, Nepal, and Malawi: a genomic epidemiological study. The Lancet Microbe 2024, 5: 100841. PMID: 38996496, PMCID: PMC11300424, DOI: 10.1016/s2666-5247(24)00047-8.Peer-Reviewed Original ResearchParatyphi ASerovars TyphiPathogenic variantsAntimicrobial resistanceSalmonella enterica serovar TyphiEnteric feverAncestral state reconstructionS paratyphi ADeterminants of antimicrobial resistanceSingle-nucleotide variantsAntimicrobial resistance determinantsQuinolone-resistance mutationsAntimicrobial resistance transmissionCore genomePhylogenomic analysisAzithromycin resistance mutationsPhylogenetic analysisGenomic dataPopulation structurePathogen diversityS typhiTransmission of resistant strainsGenomic epidemiologyAntimicrobial resistant infectionsAge groupsGlobal patterns of rebound to normal RSV dynamics following COVID-19 suppression
Thindwa D, Li K, Cooper-Wootton D, Zheng Z, Pitzer V, Weinberger D. Global patterns of rebound to normal RSV dynamics following COVID-19 suppression. BMC Infectious Diseases 2024, 24: 635. PMID: 38918718, PMCID: PMC11201371, DOI: 10.1186/s12879-024-09509-4.Peer-Reviewed Original ResearchExpanded Programme on Immunization at 50 years: its legacy and future
Wahl B, Pitzer V. Expanded Programme on Immunization at 50 years: its legacy and future. The Lancet 2024, 403: 2265-2267. PMID: 38796196, DOI: 10.1016/s0140-6736(24)00982-6.Peer-Reviewed Original ResearchEstimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020–30: a modelling study
Hartner A, Li X, Echeverria-Londono S, Roth J, Abbas K, Auzenbergs M, de Villiers M, Ferrari M, Fraser K, Fu H, Hallett T, Hinsley W, Jit M, Karachaliou A, Moore S, Nayagam S, Papadopoulos T, Perkins T, Portnoy A, Minh Q, Vynnycky E, Winter A, Burrows H, Chen C, Clapham H, Deshpande A, Hauryski S, Huber J, Jean K, Kim C, Kim J, Koh J, Lopman B, Pitzer V, Tam Y, Lambach P, Sim S, Woodruff K, Ferguson N, Trotter C, Gaythorpe K. Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020–30: a modelling study. The Lancet Global Health 2024, 12: e563-e571. PMID: 38485425, PMCID: PMC10951961, DOI: 10.1016/s2214-109x(23)00603-4.Peer-Reviewed Original ResearchConceptsCatch-up activitiesVaccine-preventable disease burdenCatch-upVaccine Impact Modelling ConsortiumImmunisation servicesMiddle-income countriesEffectiveness of HPV vaccinationVaccine effectivenessAffected cohortBill & Melinda Gates FoundationImmunisation coverageLow-incomeLong-term effectsWHO-UNICEFDisease burdenVaccination coverageCalendar yearImmunisation effortsMelinda Gates FoundationMitigation measuresCountriesYears of vaccinationYellow fever vaccineMapping the incidence rate of typhoid fever in sub-Saharan Africa
Kim J, Choi J, Kim C, Pak G, Parajulee P, Haselbeck A, Park E, Mogasale V, Jeon H, Browne A, Owusu-Dabo E, Rakotozandrindrainy R, Bassiahi A, Teferi M, Lunguya-Metila O, Dolecek C, Pitzer V, Crump J, Hay S, Marks F. Mapping the incidence rate of typhoid fever in sub-Saharan Africa. PLOS Neglected Tropical Diseases 2024, 18: e0011902. PMID: 38408128, PMCID: PMC10965079, DOI: 10.1371/journal.pntd.0011902.Peer-Reviewed Original ResearchIncidence rateSub-Saharan AfricaRate of typhoid feverTyphoid feverIncidence rate of typhoid feverIncidence rate estimatesEffective intervention programsEstimated incidence ratePublic health problemSub-SaharanHigh-incidence countriesLow-incidence countriesHealth conditionsIntervention programsDisease riskHealth problemsTarget resourcesGeospatial variationAge classesDisease incidenceEnvironmental conditionsPublished articlesSub-national heterogeneityGeospatial covariatesCultures of bloodReport from the World Health Organization’s immunization and vaccines related implementation research advisory committee (IVIR-AC) meeting, Geneva, 11–13 September 2023
Lambach P, Orenstein W, Silal S, Sbarra A, Koh M, Aggarwal R, Farooqui H, Flasche S, Hogan A, Kim S, Leask J, Luz P, Lyimo D, Moss W, Pitzer V, Wang X, Wu J. Report from the World Health Organization’s immunization and vaccines related implementation research advisory committee (IVIR-AC) meeting, Geneva, 11–13 September 2023. Vaccine 2024, 42: 1424-1434. PMID: 38326131, PMCID: PMC10953699, DOI: 10.1016/j.vaccine.2024.02.014.Peer-Reviewed Original Research
2023
Typhoid fever
Meiring J, Khanam F, Basnyat B, Charles R, Crump J, Debellut F, Holt K, Kariuki S, Mugisha E, Neuzil K, Parry C, Pitzer V, Pollard A, Qadri F, Gordon M. Typhoid fever. Nature Reviews Disease Primers 2023, 9: 71. PMID: 38097589, DOI: 10.1038/s41572-023-00480-z.Peer-Reviewed Original ResearchConceptsTyphoid feverUndifferentiated febrile illnessInvasive bacterial diseaseEffective vaccination programsFecal-oral routeNovel diagnostic modalitiesFebrile illnessBloodstream infectionsVaccination programBlood culturesClinical trialsImmunological protectionHigh burdenCausative organismDiagnostic modalitiesGlobal burdenDisease pathogenesisFeverHuman infectionsIntestinal epitheliumYoung adultsCulture testingSalmonella enterica subspSerovar TyphiAntimicrobial resistanceSurvey of white-footed mice (Peromyscus leucopus) in Connecticut, USA reveals low SARS-CoV-2 seroprevalence and infection with divergent betacoronaviruses
Earnest R, Hahn A, Feriancek N, Brandt M, Filler R, Zhao Z, Breban M, Vogels C, Chen N, Koch R, Porzucek A, Sodeinde A, Garbiel A, Keanna C, Litwak H, Stuber H, Cantoni J, Pitzer V, Olarte Castillo X, Goodman L, Wilen C, Linske M, Williams S, Grubaugh N. Survey of white-footed mice (Peromyscus leucopus) in Connecticut, USA reveals low SARS-CoV-2 seroprevalence and infection with divergent betacoronaviruses. Npj Viruses 2023, 1: 10. DOI: 10.1038/s44298-023-00010-4.Peer-Reviewed Original ResearchIncorporating Data from Multiple Endpoints in the Analysis of Clinical Trials: Example from RSV Vaccines
Prunas O, Willemsen J, Bont L, Pitzer V, Warren J, Weinberger D. Incorporating Data from Multiple Endpoints in the Analysis of Clinical Trials: Example from RSV Vaccines. Epidemiology 2023, 35: 103-112. PMID: 37793120, DOI: 10.1097/ede.0000000000001680.Peer-Reviewed Original ResearchIncorporating Efficacy Data from Initial Trials Into Subsequent Evaluations: Application to Vaccines Against Respiratory Syncytial Virus
Warren J, Sundaram M, Pitzer V, Omer S, Weinberger D. Incorporating Efficacy Data from Initial Trials Into Subsequent Evaluations: Application to Vaccines Against Respiratory Syncytial Virus. Epidemiology 2023, 35: 130-136. PMID: 37963353, PMCID: PMC10842163, DOI: 10.1097/ede.0000000000001690.Peer-Reviewed Original ResearchFloods and Diarrhea Risk in Young Children in Low- and Middle-Income Countries
Wang P, Asare E, Pitzer V, Dubrow R, Chen K. Floods and Diarrhea Risk in Young Children in Low- and Middle-Income Countries. JAMA Pediatrics 2023, 177: 1206-1214. PMID: 37782513, PMCID: PMC10546297, DOI: 10.1001/jamapediatrics.2023.3964.Peer-Reviewed Original ResearchConceptsMiddle-income countriesDiarrhea riskOdds ratioMAIN OUTCOMEMixed-effects logistic regression modelRisk of diarrheaCross-sectional studyHigher odds ratioPrevalence of diarrheaLogistic regression modelsHealth survey programUnexposed childrenEffect modificationChild healthDiarrhea prevalenceSurvey clustersSignificant associationHygiene practicesFourth weekWeeksStrong associationRandom interceptYoung childrenChildrenDiarrheaAssessing the global risk of typhoid outbreaks caused by extensively drug resistant Salmonella Typhi
Walker J, Chaguza C, Grubaugh N, Carey M, Baker S, Khan K, Bogoch I, Pitzer V. Assessing the global risk of typhoid outbreaks caused by extensively drug resistant Salmonella Typhi. Nature Communications 2023, 14: 6502. PMID: 37845201, PMCID: PMC10579367, DOI: 10.1038/s41467-023-42353-9.Peer-Reviewed Original ResearchConceptsXDR S. TyphiS. typhiDrug-resistant Salmonella enterica serovar TyphiDrug-resistant Salmonella TyphiTyphoid outbreakMajor public health threatResistant Salmonella typhiPublic health activitiesTyphoid fever incidencePublic health threatSalmonella enterica serovar TyphiXDR typhoidEnterica serovar TyphiH58 haplotypeHigh riskOnward transmissionTyphoid feverSignificant associationHealth activitiesFever incidenceHealth threatFuture outbreaksSerovar TyphiSalmonella typhiTyphiThe blossoming of methods and software in computational biology
Mac Gabhann F, Pitzer V, Papin J. The blossoming of methods and software in computational biology. PLOS Computational Biology 2023, 19: e1011390. PMID: 37590323, PMCID: PMC10434930, DOI: 10.1371/journal.pcbi.1011390.Peer-Reviewed Original ResearchYear-Round Respiratory Syncytial Virus Transmission in The Netherlands Following the COVID-19 Pandemic: A Prospective Nationwide Observational and Modeling Study
Löwensteyn Y, Zheng Z, Rave N, Bannier M, Billard M, Casalegno J, Pitzer V, Wildenbeest J, Weinberger D, Bont L, Putten M, Smit-Kleinlugtenbeld E, Peetsold M, van der Kuip M, van Goudoever H, van Keulen B, Boot A, Kloos R, van Gool S, Snepvangers Y, Kuijpers A, Menelik N, de Crom S, Miedema C, Tusscher G, van Giessen J, de Moor R, Faber M, Breukels M, Jaddoe V, Duijts L, Lutterman C, Vink I, Tramper-Stranders G, Oudshoorn A, Ritman A, Dubbink-Verheij G, Bolt J, Cakir C, Rietveld E, Bekhof J, Rings E, de Swart J, Driessen G, Doedens R, Nijssen L, van Onzenoort-Bokken L, Meijneke R, van Scherpenzeel M, Faber T, de Groof F, Schouten S, van de Zande J, de Coul M, Henriet S, Stol K, van Rossem M, Jacobs M, van Houten M, Zuurbier R, Plötz F, de Vries A, van der Heide R, van Boekholt A, de Jong G, Rashid A, Roelofs M, Illy K, Reijmerink N, van Dorth S, Schipper S, Rosias P, Teirlinck A. Year-Round Respiratory Syncytial Virus Transmission in The Netherlands Following the COVID-19 Pandemic: A Prospective Nationwide Observational and Modeling Study. The Journal Of Infectious Diseases 2023, 228: 1394-1399. PMID: 37477906, PMCID: PMC10640768, DOI: 10.1093/infdis/jiad282.Peer-Reviewed Original ResearchCOVID-19 Related Immunisation Disruptions from 2020-2030: Projecting Health Impact and Mitigation Strategies for 14 Pathogens Across 112 Low- and Middle-Income Countries
Hartner A, Li X, Echeverria-Londono S, Roth J, Abbas K, Auzenbergs M, de Villiers M, Ferrari M, Fraser K, Fu H, Hallett T, Hinsley W, Jit M, Prasinou A, Moore S, Nayagam S, Papadopoulos T, Perkins T, Portnoy A, Tran Q, Vynnycky E, Winter A, Burrows H, Chen C, Clapham H, Deshpande A, Hauryski S, Huber J, Jean K, Kim C, Kim J, Koh J, Lopman B, Pitzer V, Tam Y, Lambach P, Sim S, Woodruff K, Ferguson N, Trotter C, Gaythorpe K. COVID-19 Related Immunisation Disruptions from 2020-2030: Projecting Health Impact and Mitigation Strategies for 14 Pathogens Across 112 Low- and Middle-Income Countries. 2023 DOI: 10.2139/ssrn.4492698.Peer-Reviewed Original ResearchMedical Research CouncilHuman papillomavirusVaccine preventable disease burdenYellow fever vaccinationUK Medical Research CouncilSubsets of diseaseEDCTP2 programmeImmunisation effortsHPV vaccineFever vaccinationMiddle-income countriesImmunisation coverageVaccine coverageVaccination coverageLong-term impactDisease burdenVaccination activitiesPersonal feesSanofi PasteurAdditional deathsSpeaker feesExcess deathsMRC CentreMeningitis AEpidemiologic researchChanges in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022
Klaassen F, Chitwood M, Cohen T, Pitzer V, Russi M, Swartwood N, Salomon J, Menzies N. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical Infectious Diseases 2023, 77: 355-361. PMID: 37074868, PMCID: PMC10425195, DOI: 10.1093/cid/ciad210.Peer-Reviewed Original ResearchConceptsSevere diseasePopulation immunityOmicron infectionOmicron variantUS populationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 infectionRespiratory syndrome coronavirus 2SARS-CoV-2 Omicron variantRestoration of immunitySyndrome coronavirus 2Bayesian evidence synthesis modelInfection-acquired immunityEvidence synthesis modelSARS-CoV-2Prior immunological exposureCoronavirus 2Additional infectionsImmunological exposureInfectionDiseaseImmunityVaccinationUnited StatesAssessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis
Khanam F, Kim D, Liu X, Voysey M, Pitzer V, Zaman K, Pollard A, Qadri F, Clemens J. Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis. EClinicalMedicine 2023, 58: 101925. PMID: 37090439, PMCID: PMC10114505, DOI: 10.1016/j.eclinm.2023.101925.Peer-Reviewed Original ResearchVaccine herd protectionCluster-randomised trialHerd protectionTransmission of typhoidVi-TTTyphoid feverChildren 9 monthsVi-tetanus toxoidMonths of followJapanese encephalitis vaccineYears of ageTotal vaccine effectivenessUrban Bangladeshi childrenVaccine effectivenessEncephalitis vaccineStudy populationBangladeshi childrenTreatment centersCluster residentsIndirect effectivenessMelinda Gates FoundationTrialsVaccineAnalysis of subpopulationsFeverCost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Phillips M, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil K, Gordon M, Thindwa D, Paltiel A, Yaesoubi R, Pitzer V. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infectious Diseases 2023, 23: 143. PMID: 36890448, PMCID: PMC9993384, DOI: 10.1186/s12879-023-08105-2.Peer-Reviewed Original ResearchConceptsTyphoid Conjugate VaccineRoutine vaccinationReactive vaccinationVaccination strategiesOutbreak settingsMultidrug-resistant Salmonella typhiQueen Elizabeth Central HospitalTyphoid fever epidemicYears of ageMonths of ageCost-effectiveness analysisWorld Health OrganizationConjugate vaccineCentral HospitalRoutine immunizationVaccine deploymentPreventive vaccinationVaccinationTyphoid feverCost-effective strategyAge 15Health OrganizationFever epidemicAntimicrobial resistanceOutbreak definitions